Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia
Mark S. Chambers(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), Ingrid Armstrong(Daiichi Sankyo (United States)), Randal S. Weber(The University of Texas MD Anderson Cancer Center), Christopher U. Jones(Sutter Medical Center), Adam S. Garden(The University of Texas MD Anderson Cancer Center), Robert Vitti(Daiichi Sankyo (United States)), Y. Chen(University of Rochester), John Holland(Oregon Health & Science University), Jonathan A. Ship(Unknown), Merrill A. Biel(San Mateo Medical Center), Kenneth M. Hodge
International Journal of Radiation Oncology*Biology*Physics
September 13, 2007
Cited by 51
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926